712. Bordetella Pertussis (Bp): impact of pregnancy Tdap vaccination strategy in a pediatric hospital. Times series study. 2003-2016
Session: Poster Abstract Session: Vaccines
Thursday, October 27, 2016
Room: Poster Hall
Bordetella Pertussis (Bp): impact of pregnancy Tdap vaccination strategy in a pediatric hospital. Times series study. 2003-2016 Background: Whooping cough continues being a major cause of morbidity and mortality in infants younger than 1 year old. In 2012 Argentina introduced Tdap in pregnancy to prevent infant mortality. Objectives: to describe the clinical and epidemiological profile of Bordetella pertussis comparing pre and post Tdap vaccine periods. Methods: All laboratory PCR confirmed Bp cases between December 2003 and April 2016 were included inR. Gutierrez” Children's Hospital. Time-series analysis was performed comparing Bp cases hospitalization rates between pre-vaccination (PreV) 2003-2011 and post-vaccination (PostV) 2013-2016 periods excluding intervention year (2012).   Results: From 909 suspected cases, 324 (35.6%) were Bp confirmed cases: median age 3 months (IQ=2-6 months), 40% <3 months, 70% <6 months, 85% <12 months; 54% females; 18% had underlying conditions, the most frequent recurrent respiratory disease 73%; 1% were malnourished, 9.5% born preterm and 1% immunosuppressed; 83% required hospitalization, median length of stay was 7 days (IQ=4-12 days), 17% in UCI. Confirmed cases showed a seasonal pattern predominantly from September through February (spring-summer). Comparing pre and post Tdap: Figure 1. Lethality rate 5.3% (14/264), all fatal cases in pre Tdap period. Figure 2.   Conclusion: Confirmed cases were mostly healthy infants younger than 1 year old who had not completed their primary immunization schedule. After Tdap pregnancy vaccination strategy confirmed Bp cases were older and had less hospitalization requirements. No fatal cases occurred in our center after this intervention.  
Angela Gentile, MD1, Ana Clara Martinez, MD1, Maria Florencia Lucion, MD2, Viviana Romanin, MD1, Maria De Los Angeles Marques, Biochemistry3, Alicia Mistchenko, MD3 and Maria Del Valle Juarez, MD1, (1)Epidemiology, "R. Gutierrez" Children Hospital, Buenos Aires, Argentina, (2)"R. Gutierrez" Children Hospital, Buenos Aires, Argentina, (3)Virology, "R. Gutierrez" Children Hospital, Buenos Aires, Argentina

Disclosures:

A. Gentile, None

A. C. Martinez, None

M. F. Lucion, None

V. Romanin, None

M. D. L. A. Marques, None

A. Mistchenko, None

M. D. V. Juarez, None

See more of: Vaccines
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.